Saturday 17 October 2026
Export BIAF’s income statement to Excel — free account
bioAffinity Technologies, Inc.
BIAF Healthcare Diagnostics & Research
In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.
3.73
0.23
−5.81%
Follow BIAF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 2 | 2 | 3 |
| (245.18%) | (301.83%) | (622.65%) | (1,860.15%) | ||
| (162.88%) | (170.65%) | (235.39%) | (245.51%) | ||
ROIC |
(458.54%) | (438.42%) | (613.56%) | (408.67%) | |
Return on Tangible Assets |
(224.78%) | (302.76%) | (1,131.70%) | (1,013.64%) | |
Average Days of Receivables |
24.18 | 32.10 | 44.19 | 55.35 | |
Free Cash Flow per Share |
(119.65) | (81.79) | (36.46) | (33.16) | |
Free Cash Flow |
(8.51) | (9.39) | (10.93) | (11.56) | |
Capital Expenditures |
(0.06) | (0.06) | (0.02) | (0.09) | |
| Other line items | |||||
Cash ROIC |
(50.78%) | (65.17%) | (148.21%) | (171.18%) | |
Accounts Receivable Turnover |
7.63 | 7.33 | 6.87 | 8.96 | |
Accounts Payable Turnover |
5.67 | 4.83 | 3.42 | 3.61 | |
Inventory Turnover |
161.35 | 104.24 | 64.91 | 61.06 | |
Average Days of Payables |
70.24 | 65.79 | 80.58 | 91.73 | |
Days of Inventory on Hand |
2.63 | 4.62 | 7.51 | 7.79 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
28.60% | 33.90% | 40.06% | 45.14% | |
Selling, General and Administrative Expense of Revenue |
144.56% | 160.88% | 189.10% | 192.29% | |
Share Based Compensation of Revenue |
12.39% | 10.90% | 6.35% | 15.80% | |
Interest Coverage |
(184.08) | (237.58) | (264.59) | (275.76) | |
Operating CF/Net income |
0.57 | 0.63 | 0.69 | 0.76 | |
Depreciation/Fixed assets |
1.76 | 1.90 | 1.88 | 1.32 | |
Capex/Depreciation |
(0.11) | (0.12) | (0.03) | (0.22) | |
Revenue per Share |
95.31 | 53.68 | 18.88 | 16.93 | |
Operating CF per Share |
(118.80) | (81.26) | (36.40) | (32.90) | |
Capex per Share |
(0.85) | (0.53) | (0.05) | (0.26) | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.02 |
Columns are period end dates · fundamentals updated 2 Oct 2026